6-K 1 c93301.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------ FORM 6-K ------------ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of The Securities Exchange Act of 1934 December 21, 2005 ------------ CRUCELL NV (Exact name of registrant as specified in its charter) P.O. BOX 2048 ARCHIMEDESWEG 4 2333 CN LEIDEN THE NETHERLANDS (Address of principal executive offices) 000-30962 (Commission File Number) ------------ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F [X] Form 40-F [ ] Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ ] No [X] CRUCELL AND DSM ANNOUNCE SECOND PER.C6(R) LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS LEIDEN/SITTARD, THE NETHERLANDS, DECEMBER 21, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a second PER.C6(R) commercial license agreement with Ferring Pharmaceuticals. This license agreement allows Ferring to use the PER.C6(R) cell line in the production of a specific therapeutic protein. As with the first license, announced in May of 2005, the protein will be applied in the field of women's health care. Financial details were not disclosed. ABOUT CRUCELL Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: Sanofi Pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6(R) production technology. The company also licenses its PER.C6(R) technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com. ABOUT DSM BIOLOGICS DSM Biologics, a business unit of the DSM Pharmaceutical Products business group, is a leading contract manufacturer of biopharmaceutical products, the latest generation of drugs, mainly on the basis of native molecules and produced with the help of cell cultures. The company is renowned for its experience in the use of a broad range of cell culture systems (microbial and mammalian) and its expertise in the field of purification techniques. The company and Crucell have co-exclusive rights to license the high-producing PER.C6(R) human cell line to the pharmaceutical and biotechnology industry as a production platform for recombinant proteins and monoclonal antibodies. Established in 1986, DSM Biologics operates a manufacturing facility in Groningen, the Netherlands. For more information, please visit www.dsmbiologics.com. CRUCELL'S LICENSING PROGRAM DISCLOSURE POLICY Crucell believes it has a duty to inform (potential) investors and other stakeholders about every licensing agreement it reaches with third parties - regardless of the significance of current or future revenue or royalties generated by the agreement. Crucell fulfils this duty by issuing a press release that invariably consists of the name of the contract party, the nature of the license and an indication of the relevant technology or therapeutic area. This ensures that every potential investor or interested party can be fully up-to-date with all licensing agreements made by Crucell with third parties. An overview of all Crucell's licensees and partners can be found on the Company's website, including an overview of each relevant product's phase of development. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States. For further information please contact: Crucell N.V. Harry Suykerbuyk Director Investor Relations and Corporate Communications Tel. +31-(0)71-524 8718 h.suykerbuyk@crucell.com DSM Biologics Marcel Lubben Global Licensing Manager Tel. + 31 (0)46 47 73343 Fax. + 31 (0)46 47 73179 marcel-m.lubben@dsm.com SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CRUCELL NV ----------------------------------------- (Registrant) December 21, 2005 /s/ LEON KRUIMER ------------------------ ----------------------------------------- (Date) Leon Kruimer Chief Financial Officer